$OCUP Shares of Ocuphire Pharma (OCUP +36.2%) have jumped today after H.C. Wainwright initiated the stock with a buy rating and $26 price target (647% upside). Analyst Matthew Caulfield writes that the company is benefitting from top-line phase 3 data of Nyxol (phentolamine) in reversing mydriasis and its potential benefit in combination with pilocarpine eye drops for Presbyopia. He adds that APX3330, an oral tablet in phase 2 for diabetic retinopathy and diabetic macular edema, is undervalued. "We maintain investors have yet to fully engage with Ocuphire's Nyxol story and upcoming catalysts," Caufield says,